溴隐亭治疗垂体选择性甲状腺激素抵抗的疗效。

Efficacy of bromocriptine administration for selective pituitary resistance to thyroid hormone.

作者信息

Ohzeki T, Hanaki K, Motozumi H, Ohtahara H, Ishitani N, Urashima H, Tsukuda T, Shiraki K, Sasaki S, Nakamura H

机构信息

Department of Pediatrics, Faculty of Medicine, Tottori University, Yonago, Japan.

出版信息

Horm Res. 1993;39(5-6):229-34. doi: 10.1159/000182741.

DOI:10.1159/000182741

PMID:8314208

Abstract

The relation between thyroid-stimulating hormone (TSH) and triiodothyronine (T3) was evaluated in a girl with the selective pituitary type of thyroid hormone resistance for more than 7 years to clarify whether bromocriptine was an effective treatment or not. Levels of T3 (before: 2.44 +/- 0.64 nmol/l, mean +/- SD) and TSH (4.81 +/- 2.52 mU/l) were significantly decreased during therapy (T3: 2.15 +/- 0.44 nmol/l; TSH: 1.59 +/- 0.78 mU/l). T3 x TSH, calculated as one of the indices of pituitary resistance, on bromocriptine therapy (3.229 +/- 1.255 mU/l x nmol/l) was significantly (p < 0.005) smaller than the product before the administration (11.298 +/- 5.891 mU/l x nmol/l). The results suggest that bromocriptine should be one of the agents initially considered for the treatment of pituitary resistance to thyroid hormone.

摘要

为明确溴隐亭是否为有效的治疗药物，对一名患有选择性垂体型甲状腺激素抵抗超过7年的女孩，评估了促甲状腺激素（TSH）与三碘甲状腺原氨酸（T3）之间的关系。治疗期间，T3水平（治疗前：2.44±0.64nmol/L，均值±标准差）和TSH水平（4.81±2.52mU/L）显著降低（T3：2.15±0.44nmol/L；TSH：1.59±0.78mU/L）。作为垂体抵抗指标之一计算的T3×TSH，在溴隐亭治疗时（3.229±1.255mU/L×nmol/L）显著（p<0.005）小于给药前的乘积（11.298±5.891mU/L×nmol/L）。结果表明，溴隐亭应是最初考虑用于治疗垂体性甲状腺激素抵抗的药物之一。